Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020

BACKGROUND: The majority of current pharmacological treatments for Parkinson’s disease (PD) were approved for clinical use in the second half of the last century and they only provide symptomatic relief. Derivatives of these therapies continue to be explored in clinical trials, together with potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarthing, Kevin, Buff, Sue, Rafaloff, Gary, Dominey, Thea, Wyse, Richard K., Stott, Simon R.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Clinical Trials Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458531/
https://www.ncbi.nlm.nih.gov/pubmed/32741777
http://dx.doi.org/10.3233/JPD-202128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458531/
https://www.ncbi.nlm.nih.gov/pubmed/32741777
http://dx.doi.org/10.3233/JPD-202128

Ejemplares similares